Johnson & Johnson Initiates Pivotal Head-to-Head Trial of Pulsed Field Ablation in Persistent Atrial Fibrillation
Johnson & Johnson has announced the initiation of a landmark clinical study aimed at advancing the scientific understanding of pulsed field ablation (PFA), a rapidly evolving technology used to treat cardiac arrhythmias. The study, known as the PERSIGMA randomized controlled trial (RCT), represents one of the first rigorous, head-to-head comparisons of competing PFA technologies—an important step toward generating high-quality evidence in a field that has seen swift innovation but limited direct comparative data.
As electrophysiology continues to evolve, clinicians are increasingly adopting PFA as a promising alternative to traditional thermal ablation techniques. However, despite its growing use, there remains a lack of randomized studies directly comparing different PFA systems. The PERSIGMA trial is designed to address this gap by evaluating how distinct technologies perform relative to one another in real-world clinical settings, particularly in patients with more advanced forms of heart rhythm disorders.
The trial will enroll up to 466 participants across approximately 50 clinical sites, reflecting a broad and diverse patient population. Participants will be randomly assigned to receive treatment with either the VARIPULSE Pro Platform—Johnson & Johnson’s next-generation PFA system—or the control FARAPULSE PFA platform, another widely used technology in the field. By incorporating randomization and a controlled design, the study aims to minimize bias and provide robust, clinically meaningful insights into the comparative safety and effectiveness of these systems.
The focus of the PERSIGMA trial is on patients with Atrial Fibrillation (AFib), specifically those with persistent forms of the condition. AFib is the most common sustained cardiac arrhythmia worldwide and represents a significant and growing public health challenge. It is characterized by irregular and often rapid heart rhythms that can lead to symptoms such as palpitations, fatigue, and shortness of breath. More importantly, AFib significantly increases the risk of stroke, heart failure, and other cardiovascular complications.
The disease typically progresses over time. Many patients initially experience paroxysmal AFib, in which episodes are intermittent and may resolve spontaneously. However, as the condition advances, it can become persistent, meaning episodes last longer than seven days and often require medical intervention to restore normal heart rhythm. Persistent AFib is generally more complex to treat, making it a critical focus area for innovation in electrophysiology.
The primary endpoints of the PERSIGMA trial are centered on both safety and effectiveness. Safety will be assessed by monitoring the occurrence of major adverse events associated with the procedure, while effectiveness will be measured by the absence of arrhythmia recurrence during a defined evaluation period beginning 60 days after the procedure. These endpoints are designed to capture both the immediate procedural risks and the longer-term success of the treatment in maintaining normal heart rhythm.
A key feature of the study is its evaluation of the VARIPULSE Pro Platform, which recently received CE mark approval in Europe but has not yet been approved for use in the United States. This next-generation system builds on earlier PFA technologies by incorporating optimized pulse sequences and improved irrigation rates, with the goal of enhancing procedural efficiency and clinical outcomes. The platform is also integrated with the CARTO System, a sophisticated ecosystem that combines imaging, mapping, and therapeutic capabilities to support precise and personalized treatment.
This integration reflects a broader trend in cardiovascular care toward connected technologies that enable clinicians to visualize and treat cardiac arrhythmias with greater accuracy. By combining mapping and ablation in a unified platform, systems like VARIPULSE Pro aim to streamline workflows and improve the consistency of results across different patient populations.
The development of VARIPULSE Pro is part of Johnson & Johnson’s broader strategy to continuously evolve its electrophysiology portfolio through iterative innovation. The company has emphasized multigenerational advancements in PFA technology, supported by clinical data from studies such as VARIPURE, which has demonstrated encouraging safety and performance outcomes at 12 months. Additional real-world evidence is expected to be presented at major scientific meetings, including upcoming cardiology and electrophysiology conferences.
Clinical leaders in the field have highlighted the importance of the PERSIGMA trial in shaping future treatment decisions. Devi Nair, Director of Cardiac Electrophysiology and Research at St. Bernard’s Medical Center and co-national principal investigator of the study, emphasized that direct comparisons between PFA technologies are essential for informed clinical practice. According to Nair, the availability of head-to-head data will help physicians better understand the relative strengths and limitations of different systems, ultimately improving patient care.
The trial has also been featured at prominent scientific gatherings, including the Heart Rhythm 2026 Congress in Chicago, where early procedural experiences from the study were presented. These initial insights provide a glimpse into how the technologies perform in practice and offer valuable feedback for clinicians adopting PFA in their treatment strategies.
Andrea Natale, Executive Medical Director of the Texas Cardiac Arrhythmia Institute and co-national principal investigator of the PERSIGMA trial, described the study as a critical step forward in the evolution of PFA research. He noted that as the technology is applied to more complex patient populations, including those with persistent AFib, rigorous clinical evidence becomes increasingly important. Studies like PERSIGMA not only help refine procedural techniques but also contribute to a deeper understanding of how best to optimize outcomes for patients.
From an industry perspective, the trial underscores Johnson & Johnson’s commitment to advancing evidence-based innovation in cardiovascular care. Gregory Michaud, Chief Medical and Scientific Officer for Electrophysiology at Johnson & Johnson, highlighted the need for comparative data in a field where rapid technological progress has outpaced the generation of robust clinical evidence. He noted that physicians often make decisions without direct comparisons between available technologies, and the PERSIGMA trial aims to address this gap by raising the standard for evaluation.
Beyond the immediate findings, the study is expected to contribute to a growing body of research supporting the use of PFA in treating atrial fibrillation. By expanding the evidence base, Johnson & Johnson aims to strengthen confidence in its technologies and support broader adoption of PFA as a standard treatment option. This is particularly important as the company seeks to extend the use of PFA to a wider range of patients, including those with more advanced or complex forms of the disease.
The broader cardiovascular portfolio of Johnson & Johnson MedTech reflects a comprehensive approach to addressing some of the most pressing health challenges worldwide. In addition to electrophysiology, the company is actively developing solutions for conditions such as heart failure, coronary artery disease, and stroke—areas that represent leading causes of morbidity and mortality globally. Through innovations in mapping, navigation, and minimally invasive therapies, the company aims to provide clinicians with the tools needed to deliver more precise and effective care.
Ultimately, the initiation of the PERSIGMA randomized controlled trial marks a significant milestone in the evolution of pulsed field ablation technology. By prioritizing rigorous, head-to-head comparisons, the study sets a new benchmark for how emerging medical technologies are evaluated. For patients living with atrial fibrillation, particularly those with persistent disease, this research holds the promise of improved treatment options and better long-term outcomes.
As the trial progresses, its findings are likely to influence clinical practice, guide future innovation, and shape the next generation of therapies for cardiac arrhythmias. In a field where precision and safety are paramount, the generation of high-quality evidence is essential—and PERSIGMA represents a decisive step in that direction.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.
Source Link:https://www.jnj.com/
